About Orchid Pharma Limited

Orchid Pharma Limited is an Indian pharmaceutical company headquartered in Chennai, engaged in development, manufacturing and marketing of bulk actives (APIs), formulations, and nutraceuticals with exports spanning over 40 countries. Its manufacturing infrastructure includes USFDA-compliant API and Finished Dosage Form facilities in Chennai, supported by GLP-compliant R&D centres for process research, drug discovery, and pharmaceutical research in Chennai; the company holds ISO 14001 and OHSAS 18001 certifications, and its equity shares are listed on NSE and BSE in India. Pursuant to an approved resolution plan, Dhanuka Laboratories Limited (through Dhanuka Pharmaceuticals Private Limited) implemented the plan on March 31, 2020; the SPV merged into Orchid thereafter, making Orchid a subsidiary of Dhanuka Laboratories Limited effective March 31, 2020. As part of the group structure, subsidiaries include Orchid Pharmaceuticals Inc., USA; Bexel Pharmaceuticals Inc., USA; Diakron Pharmaceuticals Inc., USA; and Orchid Pharmaceuticals SA (Proprietary) Limited, South Africa, which was wound up on January 31, 2024, with certain foreign subsidiaries’ financials unaudited and consolidated by management for FY 2024–25. The consolidated statements indicate continuing operations with global presence and a focus on regulated markets, while historical pre-CIRP liabilities were settled per the resolution plan and extinguished as of March 31, 2020.

Orchid Pharma Limited Business Segments

• Revenue mix by product/vertical: Not specifically disclosed in segmental percentage terms in the report; the company presents standalone revenue from operations of Rs 921.93 crore for FY 2024–25 and Rs 819.37 crore for FY 2023–24 under a single operating profile without disclosed segment percentages by vertical. 

Orchid Pharma Limited Key Management

• Manish Dhanuka — Managing Director. 
• Mridul Dhanuka — Wholetime Director. 
• Sunil Kumar Gupta — Chief Financial Officer. 
• Kapil Dayya — Company Secretary. 

Latest Updates on Orchid Pharma Limited

• FY 2024–25 standalone revenue from operations was Rs 921.93 crore with profit before tax of Rs 106.48 crore and profit after tax of Rs 105.73 crore, reflecting operational profitability and growth over the prior year; earnings per share (basic/diluted) stood at Rs 20.99. 
• Consolidated revenue from operations was Rs 921.93 crore with profit after tax of Rs 99.66 crore; consolidated EPS (basic/diluted) was Rs 19.65 for FY 2024–25, indicating sustained consolidated profitability. 
• Orchid Pharmaceuticals SA (Proprietary) Limited, South Africa, was wound up on January 31, 2024; consolidation for FY 2024–25 used unaudited financials for certain overseas subsidiaries due to local audit non-requirements and minimal activity. 
• Auditors issued an unmodified opinion on standalone results for year ended March 31, 2025; the CARO and internal financial controls reports noted adequate controls operating effectively as at March 31, 2025. 
• Prior pre-CIRP statutory and other claims were addressed under the approved resolution plan, with pending litigations for the pre-CIRP period deemed extinguished as of the implementation date; certain disputed GST matters remain disclosed without impacting going concern.